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Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is a genetic disorder displaying features reminiscent of premature
senescence caused by germline mutations in the LMNA gene encoding lamin A and C, essential components of the nuclear
lamina. By studying a family with homozygous LMNA mutation (K542N), we showed that HGPS can also be caused by
mutations affecting both isoforms, lamin A and C. Here, we aimed to elucidate the molecular mechanisms underlying the
pathogenesis in both, lamin A- (sporadic) and lamin A and C-related (hereditary) HGPS. For this, we performed detailed
molecular studies on primary fibroblasts of hetero- and homozygous LMNA K542N mutation carriers, accompanied with
clinical examinations related to the molecular findings. By assessing global gene expression we found substantial overlap in
altered transcription profiles (13.7%; 90/657) in sporadic and hereditary HGPS, with 83.3% (75/90) concordant and 16.7%
(15/90) discordant transcriptional changes. Among the concordant ones we observed down-regulation of TWIST2, whose
inactivation in mice and humans leads to loss of subcutaneous fat and dermal appendages, and loss of expression in dermal
fibroblasts and periadnexial cells from a LMNA
K542N/K542N patient further confirming its pivotal role in skin development.
Among the discordant transcriptional profiles we identified two key mediators of vascular calcification and bone
metabolism, ENPP1 and OPG, which offer a molecular explanation for the major phenotypic differences in vascular and bone
disease in sporadic and hereditary HGPS. Finally, this study correlates reduced TWIST2 and OPG expression with increased
osteocalcin levels, thereby linking altered bone remodeling to energy homeostasis in hereditary HGPS.
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Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is a genetic
disorder caused by mutations in the lamin A/C gene (LMNA), a
component of the nuclear lamina [1]. Within the broad spectrum
of phenotypes caused by LMNA germline mutations (known as
laminopathies), HGPS belongs to the distinct group of segmental
progeroid syndromes, displaying features reminiscent of premature
senescence [2,3]. The main tissues affected in HGPS are of
mesenchymal origin, and include adipose tissue, bone, cartilage
and the cardiovascular system. Progeria is a progressive disease:
Affected children appear normal at birth, but begin to develop
characteristic symptoms within the first years of life. The main
symptoms of HGPS include growth retardation, generalized
lipodystrophy (cachexia), osteoporosis and osteolysis, decreased
joint mobility, joint stiffness, skin atrophy, hair loss and
cardiovascular changes resulting in death on average at 12 to 13
years of age [4,5].
The LMNA gene encodes two A-type lamins, lamin A and C,
which are the result of alternative splicing. Generated lamin A and
C share the first 566 amino acids and differ by the 98 and 6 amino
acids at their C-terminal end, respectively. Pre-lamin A, but not
lamin C, is subjected to several posttranslational modifications,
during which its C terminus is modified by farnesylation, followed
by endoproteolytic cleavage by the Zmpste24 protease [6]. The A-
type lamins, together with B-type lamins, are type V intermediate
filament proteins that form a filamentous meshwork underlying
the inner membrane of the nuclear envelope, known as the nuclear
lamina. Through their direct or indirect interaction with many
known nuclear membrane and nucleoplasmic proteins lamins
were shown to be involved in a number of essential nuclear
functions, including maintenance of nuclear integrity, DNA
replication, transcription organization, replication, and DNA
repair [7,8,9]. In contrast to B-type lamins, which are ubiquitously
expressed in all cell types at all developmental stages [7,10,11], A-
type lamins are expressed in differentiated tissues, mesenchymal
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including embryonic stem cells, and exist at very low level or are
absent in hematopoietic cells [12,13,14,15].
The vast majority of HGPS patients are sporadic cases caused
by a de novo heterozygous germline mutation c.1824C . T
(p.G608G) which generates a cryptic splice site in exon 11 of
LMNA, and leads to an in-frame deletion of 50 amino acids in pre-
lamin A [16,17]. The mutant protein, so called ‘‘progerin‘‘, lacks
the cleavage site for the enzyme Zmpste24, thus preventing the
final cleavage step in the pre-lamin A posttranslational processing.
As a consequence, lamin A remains permanently carboxyfarne-
sylated and methylated, which leads to its abnormal incorporation
into the nuclear lamina and thickening of the nuclear lamina and a
large spectrum of nuclear abnormalities [18,19,20,21].
Initially it was thought that HGPS is merely a lamin A-related
laminopathy, caused by constitutive production of progerin. By
studying a HGPS family with parental consanguinity, our research
group was the first to provide evidence that HGPS can also be
caused by homozygous mutations (c.1626G.C; p.K542N)
affecting both, lamin A and C, thus challenging the prevailing
hypothesis that HGPS merely represents a lamin A-related
laminopathy [4]. This observation was further supported by the
identification of other lamin A/C-related LMNA mutations in
patients with progeroid disorders [22,23,24], showing that
progerin or pre-lamin A accumulation is not the major
determinant of the progeroid phenotype.
In order to elucidate the molecular mechanisms underlying the
pathogenesis in both, lamin A- (sporadic) and lamin A/C-related
(hereditary) HGPS, we performed detailed molecular studies on
primary fibroblasts of hetero- and homozygous K542N mutation
carriers, accompanied with clinical examinations related to the
molecular findings. Here, we show that there is substantial overlap
in altered gene expression profiles between G608G- (sporadic) and
K542N-related (hereditary) HGPS. The concordant as well as the
discordant transcriptional changes point to common pathogenic
processes underlying both types of HGPS and offer molecular
explanations for the major differences in disease expression,
namely bone and cardiovascular disease as well as altered energy
homeostasis.
Results
Molecular characterization of LMNA K542N
In contrast to the lamin A specific G608G mutation, the
homozygous LMNA missense mutation (c.1626G.C, p.K542N)
identified in the consanguineous HGPS family alters the coding
sequence shared by both splice variants and thus affects both,
lamin A and C. RT-PCR analysis of RNA extracted from cultured
fibroblasts of two K542N homozygous patients, healthy heterozy-
gous parents and sister confirmed, as predicted by in silico splice
site analysis [4], that the c.1626G.C mutation neither affects
lamin A/C mRNA splicing nor introduces a novel splice site
(Figure S1). To assess whether K542N affects expression and
processing of A-type lamins, we undertook Western blot analysis of
total protein extracts from fibroblasts using lamin A specific
(133A2), and lamin A and C specific antibodies (JOL5). Western
blots neither revealed any difference in lamin A and C expression
patterns nor gave evidence for prelamin A or aberrant sized lamin
A/C accumulation in patients (n=2) when compared with healthy
family members (n=3) and control (Figure S2). This observation is
consistent with our previous assumption that K542N does not
affect lamin A processing since the mutation is localized outside
the region recognized by Rce1 and Zmpste24, enzymes involved
in posttranslational modifications [4].
Nuclear abnormalities in LMNA K542N fibroblasts
Cultured cells from sporadic HGPS patients carrying the
progerin mutation were shown to exhibit a variety of alterations in
nuclear morphology [18,19,20,21]. To assess the nuclear pheno-
type in K542N mutation carriers we examined primary cultured
fibroblasts from affected and healthy family members by
immunofluorescence. The nuclei of K542N carriers showed one
or two extensive protrusions frequently present at opposite poles,
accompanied with honeycomb and/or tubule-like lamin struc-
tures. DAPI counterstaining of DNA revealed that some of the
protrusions show envelope rupture accompanied by chromatin
extrusion (Figure 1). These nuclear abnormalities were present in
approximately 28% of nuclei from homozygous K542N mutation
carriers (n=3) and in 5% of nuclei from healthy heterozygous
carriers (n=3; 28% vs. 5%, p,0.0001). Control fibroblasts (n=3)
showed a similar percentage of nuclear envelope alterations (3%)
as observed in the heterozygotes, but the morphological changes
were different from those observed in K542N carriers and neither
chromatin extrusion nor honeycomb structures were displayed.
Lamin B1 stain was found to be reduced to absence in nearly all
patient’s nuclear protrusions (Figure 1A). Immunostaining for
emerin and LAP2, whose interaction with A-type lamins is
expected to be impaired by K542N, both showed abnormal
localization within these protrusions. Increased emerin presence
was detected in the majority of nuclear protrusions. In the large
blebs, emerin showed the honeycomb pattern, which frequently
overlapped with that of lamin A (Figure 1B). Interestingly, striking
LAP2 accumulation was identified at the frontal edge of nearly all
nuclear protrusions even though lamin A was frequently absent in
these regions (Figure 1C). These observations support the
assumption that the K542N mutation impairs the interaction of
the A-type lamins with LAP2 [4]. In particular, failure of the LAP2
protein to colocalize with lamin A points to a derangement of
lamin A-LAP2 complexes by K542N [25].
To differentiate whether the misshapen nuclei are restricted to
fibroblasts (or culture artifacts), we performed immunohistochem-
ical (IHC) staining of lamin A in skin and liver autopsy specimens
from a deceased homozygous K542N carrier. In contrast to
control samples, the majority of patient’s hepatocyte nuclei showed
an irregular nuclear contour (32% vs. 4.1%, p,0.0001), i.e.
wrinkled nuclear shape with protrusions and occasional spikes.
IHC analysis of the skin specimen revealed similar, but less striking
changes (Figure 2A). We thus provide direct evidence that nuclear
envelope alterations, which have been considered a pathological
hallmark of cultured HGPS cells [18,20,26], are already present in
vivo [18,20,26,27].
Comparison of global gene expression in lamin A- and
lamin A/C-related HGPS
With the aim to elucidate the molecular mechanisms underlying
the pathogenesis in both, lamin A- (sporadic) and lamin A/C-
related (hereditary) HGPS, we investigated primary cultured skin
fibroblasts from affected homozygous K542N carriers (LMNA
K542/
K542N; n=3), healthy heterozygotes (LMNA
K542/+; n=3), and
controls (n=3) for differences in global gene expression using
GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix UK
Ltd.). Comparison of the LMNA
K542/K542N transcriptional profile
with the ones from healthy carriers and controls revealed at least
1.5 fold expression changes in 657 and more than 2 fold changes
in 278 genes (Table S1), from which a selection of 19 altered
transcripts could be confirmed by subsequent TaqMan gene
expression assays (Table S2). Expression changes ranged from
27.06 to +10.7 fold. Analysis of differentially expressed genes
revealed that the K542N mutation leads to deregulation of genes
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as in tissue development.
Since sporadic and hereditary HGPS show considerable clinical
overlap we wondered about the degree of concordance in
transcriptional signatures between K542N and G608G fibroblasts.
Comparison of our results with the two published gene expression
microarray experiments on fibroblast cell lines from patients
carrying the G608G mutation revealed substantial overlap in
altered transcription patterns (13.7%; 90/657) between sporadic
and hereditary HGPS (Table 1). Of these, 78 genes overlapped
with the study by Csoka et al. (86.6%, 78/90; [28]), 23 with study
of Wang et al. (25.5%, 23/90; [29]), and 11 with both (12.2%; 11/
90). Ten of them were subsequently confirmed by TaqMan
expression assays (Table S2). Recently, the third global expression
profiling on fibroblasts from patients with sporadic HGPS was
reported [30], however, since the authors did not publish the list of
differentially expressed genes, we could not include them in our
comparative study.
With regard to the overlapping genes, the transcriptional
changes observed in LMNA
G608G/+ cell lines were usually higher,
ranging from 26.8 to 29.1-fold and from -29.56 to 51.85-fold,
respectively [28,29], compared to LMNA
K542/K542N fibroblasts
(26.46 to 7-fold). Twenty-seven of the overlapping genes (30.0%;
27/90) showed only 1.5–2 fold expression changes in LMNA
K542/
K542N cells, and therefore would have been missed applying a 2-
fold change cutoff. These differences may partly reflect true
differences related to the particular LMNA mutation, and/or be
due to differences in methodology and passage number, as the
LMNA
G608G/+ cells obtained from the Corriell Cell Repository are
usually of later passages (.10) and the authors did not specify the
passage number of the fibroblasts used [28,29].
Analysis of the common transcriptional signatures of sporadic
and hereditary HGPS fibroblasts revealed that 83.3% (75/90) of
the genes had concordant (matching) and 16.7% (15/90)
discordant (opposite) transcription patterns (Table S3A and S3B,
respectively). Interestingly, the overlap between the G608G and
K542N fibroblasts’ gene expression profiles was higher than
between the two G608G studies alone. Importantly, the
differentially expressed genes common to all three studies showed
matching transcriptional changes (Table 1 and Table S4).
Concordant (matching) transcriptional signatures
One of the genes that showed concordant transcriptional
alteration in both LMNA
K542/K542N and LMNA
G608G/+ cells was
TWIST2 (also known as DERMO1), a known transcription factor
important for osteoblast differentiation [31], whose knock-out
mouse models display a cachectic phenotype similar to HGPS, i.e.
postnatal failure to thrive, growth retardation, adipose deficiency,
and perinatal death [32]. Analogous to cachectic mice, TWIST2
expression was found to be 3 fold decreased in the LMNA
G608G/+
cells [28], and 3.5 fold decreased (p=0.00011) in LMNA
K542/K542N
fibroblasts which was confirmed by two TaqMan expression assays
(fold change of 23.2, p=0.016, and of 22.9, p=0.016).
To assess TWIST2 protein expression in vivo we investigated
skin and liver autopsy specimens from a deceased K542N
homozygous patient. Immunohistochemical analysis confirmed
decreased cytoplasmic TWIST2 expression levels in the patient’s
hepatocytes when compared to corresponding specimens from
healthy controls, and revealed loss of nuclear TWIST2 in the
majority of patient’s hepatocytes (Figure 2B). The absence of
nuclear TWIST2 in Kupffer and endothelial cells in both patient’s
and control’s liver specimens excluded the possibility of a technical
artifact. In skin epidermis, TWIST2 staining did not reveal any
apparent expression differences between patient and control. In
the patient’s dermis, however, selective loss of TWIST2 was
detected in most periadnexial and fibroblast cells, which is in
accordance with the decreased TWIST2 transcription levels we
observed in cultured fibroblasts by microarrays and TaqMan
assays.
Because Twist2 mutant mice also manifest abnormalities in
glucose metabolism and storage, evidenced by hypoglycemia and
absence of glycogen in skeletal muscle and liver, as well as by
elevated transcription of proinflammatory cytokines (TNFa and
IL-1b) in skin, skeletal muscle, and cultured skin fibroblasts [32],
we wondered if TWIST2 down-regulation could result in similar
molecular and biochemical changes in our patient(s). Periodic
acid-Schiff (PAS) staining for glycogen performed on the liver
autoptic specimen from the deceased patient did not reveal any
obvious quantitative changes (data not shown). Similarly, serum
TNFa assessment in two homozygous patients and their
heterozygous parents, as well as the microarray results on TNFa
did not show any differences between affected and healthy family
members (data not shown). Microarray analysis, however, revealed
almost 50% up-regulation of IL-1b in patients’ cultured fibroblasts
(fold change=1.41, p,0.01), the finding subsequently confirmed
by TaqMan analysis (fold change of 4.38, p=0.044, and of 4.50,
p=0.046). Glucose assessment, performed within oral glucose
tolerance testing (oGTT; see below) in two patients and their
parents, revealed a fasting glucose at the lower normal level in
both patients (Table S5).
Discordant (opposite) transcriptional signatures
Given that 16.7% (15/90) of the overlapping genes in sporadic
and hereditary HGPS showed opposite transcriptional changes,
we wondered whether some of these findings might help to explain
differences in disease expression. Interestingly, two genes,
TNFRSF11B and ENPP1, whose mutations are associated with
distinct disease phenotypes present in HGPS were found to have
opposite transcriptional changes in LMNA
K542/K542N and
LMNA
G608G/+ fibroblasts (Table S3B; [28]).
TNFRSF11B, also known as osteoprotegerin (OPG), is a member
of the OPG/RANKL/RANK cytokine triad controlling osteoclasto-
genesis and bone remodeling, which was recently identified as a
mediator of vascular calcification. Its increased serum levels were
shown to be associated with vascular calcification, coronary artery
disease, stroke and cardiovascular events [33,34]. In microarray
experiments OPG expression was increased 3 fold in LMNA
G608G/+
cell lines [28] and 2.3 fold decreased (p=0.023) in the LMNA
K542/
K542N fibroblasts, which was also confirmed by two TaqMan assays
(fold change of 22.27, p=0.052, and of 22.41, p=0.037). These
findings thus demonstrate an inverse correlation between OPG
expression and atherosclerotic heart disease in sporadic and
hereditary HGPS.
In addition to TNFRSF11B, the cardiovascular phenotype in
sporadic and hereditary HGPS also correlated with ENPP1
expression. ENPP1, an ectonucleotide pyrophosphatase phospho-
diesterase 1 (known also as plasma cell antigen 1, PC-1), is a
widely expressed cell surface enzyme which generates inorganic
Figure 1. Fibroblast nuclei from the LMNA
K542/K542N patient and healthy control. (A) Immunofluorescence staining for lamin A and lamin B1.
(B) Immunofluorescence microscopy using lamin A and emerin antibodies. (C) Confocal microscopy using lamin A and LAP2 antibodies. Scale bar,
10 mM.
doi:10.1371/journal.pone.0021433.g001
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inhibitor of calcification [35]. In addition, ENPP1 was shown to be
an inhibitor of the insulin signaling pathway, through its direct
interaction with the insulin receptor [36]. Consistently with its
dual function, ENPP1 inactivating mutations caused generalized
arterial calcification of infancy (GACI; [35]), and over-expression
of ENPP1 has been found to be associated with human insulin
resistance in non-insulin-dependent diabetes mellitus [36,37].
Microarray experiments showed that ENPP1 expression was 2.4
fold (p=0.024) increased in LMNA
K542/K542N fibroblasts and 6.8
fold decreased in LMNA
G608G/+ fibroblast cell lines [28]. TaqMan
expression analysis in LMNA
K542/K542N fibroblasts confirmed the
ENPP1 expression changes, but did not reach statistical signifi-
cance (fold change of 3.00, p=0.064, and of 3.32, p=0.055).
Cardiological examination in three patients (aged 4–17 years at
time of referral) was unremarkable. Systolic and diastolic blood
pressures were within the lower normal age- and sex-related
ranges (patient R: 95/65 mmHg; patient E: 100/70 mmHg;
patient A: 95/65 mmHg). Pulse rates were at the upper normal
levels (116–120/min). Electrocardiogram and echocardiographic
investigations showed no pathological findings. Imaging studies
(CT) of the heart and the large vessels gave no evidence for
atherosclerotic alterations in any of the patients. These findings
match with the cause of death observed in the hereditary HGPS
patients. Unlike patients with sporadic HGPS in whom the cause
of death is usually of vascular origin [2,38], all deceased K542N
homozygous patients, two previously reported (at age 10 and 19
years [4]) and two recently deceased (at age 21 and 21 years), died
of respiratory failure due to severe pneumonia. The pulmonary
infections resulted from hypoventilation due to progressive rib
resorption and subsequent rib cage instability. Taken together, the
normal cardiovascular findings in the three patients investigated
are in accordance with increased ENPP1 expression levels
observed in the homozygous K542N fibroblasts. This observation
is further supported by up-regulation of osteopontin (OPN, also
known as secreted phosphoprotein 1, SPP1), whose expression in
mice was shown to be positively regulated by ENPP1, through the
inorganic pyrophosphate level [39]. Up-regulation of SPP1 in
LMNA
K542/K542N fibroblasts was detected by both microarrays and
TaqMan expression assay (fold change of 2.7, p=0.0026, and of
14.2, p=0061, respectively), thus further confirming the correla-
tion of increased ENPP1 expression levels with an unremarkable
cardiovascular status in hereditary HGPS.
In an effort to clarify whether increased expression of ENPP1 is
associated with insulin resistance and diabetes in LMNA K542N
homozygotes, oral glucose tolerance testing (oGTT) was per-
formed on both healthy parents and two affected children (at age
10 and 20 years; Table S5B). In both homozygous patients glucose
concentration at fasting (0 minutes of oGTT) and after glucose
load (120 minutes of oGTT) was found to be at low normal level
and did not increase postprandially, thus excluding diabetes
mellitus type 2, impaired fasting glucose or impaired glucose
tolerance. Fasting insulin levels were within the lower normal
range and showed nearly no increase of insulin at 120 minutes
after glucose load. Intriguingly, C-peptide measurements in the
affected sibs were repeatedly found to be very low, with apparent
age-dependent pattern (ranging from 0.24 to 0.08 nmol/L; Table
S5), correlating with decreased insulin levels and suggesting
increased insulin sensitivity. Nonlinear homeostatic model assess-
ment (HOMA2; [40]), using two independent, one year consec-
utive measurements of fasting insulin, C-peptide, and fasting
glucose, revealed decreased insulin resistance (HOMA2-IR,0.5),
strongly increased insulin sensitivity (.240%), and decreased b–
cell function (,77%) in LMNA K542N homozygotes (Table S5A).
High insulin sensitivity was further confirmed by the insulin
sensitivity indices derived from oGTT (Matsuda and Cederholm
index, Table S5B; [41,42,43]). In contrast to the K542N
homozygous children, the heterozygous parents met the criteria
for impaired glucose tolerance (mother) and diabetes (father). They
showed no insulin resistance (HOMA-IR=1), normal to moder-
ately increased insulin sensitivity (Matsuda and Cederholm index),
but decreased b–cell response to glucose uptake (Table S5). To
further investigate possible reasons for the observed increase in
insulin sensitivity, we measured osteocalcin, an osteoblast-specific
protein which acts as a hormone regulating insulin production and
sensitivity [44]. Total serum osteocalcin levels were found to be
elevated in both patients (106 ug/L [normal range at age 10y:
24.0–70.0] and 50.5 ug/L [normal range at age 20y: 14.0–42.0],
respectively), but not in their parents. Taken together, ENPP1 up-
regulation observed in the homozygous patients is not associated
with insulin resistance. Increased insulin sensitivity, however,
observed in two consecutive laboratory investigations is in
accordance with increased levels of total osteocalcin.
Differentially expressed genes unique to LMNA
K542/K542N
fibroblasts
We realized that more than 200 of the differentially expressed
genes encode proteins that are either secreted into extracellular
environment or are known membrane anchored proteins affecting
signaling of adjacent cells, indicating that deranged gene
expression in fibroblasts might indirectly influence differentiation
and activity of neighboring cells. Among these genes we identified
the Wnt5a ligand, a known wnt secreted signaling protein involved
in the cell-lineage decision of mesenchymal stem cells when they
differentiate into adipocytes or osteoblasts [45]. WNT5A deregu-
lation was exclusively observed in LMNA
K542/K542N fibroblasts.
Both, microarray and TaqMan gene expression analysis, showed
up-regulation in K542N homozygous fibroblasts compared to
heterozygous and control fibroblasts (fold change of 2.82,
p=0.00084; and of 3.98, p=0.026, respectively). Immunohisto-
Figure 2. Immunohistochemical analysis in skin and liver autoptic specimens from a deceased LMNA
K542/K542N patient.
(A) Immunohistochemistry for lamin A. (B) Immunohistochemical staining for Twist2. Arrow indicates Twist2 loss in the periadenexial cells (PC) of
the dermis in the skin and in the Kupffer (KC) and endothelial cells (EC) of the liver. (C) Immunohistochemistry for Wnt5a. Scale bar, 10 mM.
doi:10.1371/journal.pone.0021433.g002
Table 1. Overlap between LMNA K542N and G608G
expression signatures.
LMNA
K542/K542N
LMNA
G608G/+
[28]
LMNA
G608G/+
[29]
LMNA
K542/K542N 1 11.9% (78/657) 3.5% (23/657)
LMNA
G608G/+ [28] 21.6% (78/361) 1 5.5% (20/361)
LMNA
G608G/+ [29] 41.1% (23/56) 35.7% (20/56) 1
Comparison between transcriptional signature in LMNA
K542/K542N fibroblasts and
the two published transcriptional signatures in LMNA
G608G/+ fibroblast cell lines
[28,29]. Total number of gene transcripts compared: this study, n=657, Csoka
et al. [28]: n=361, Wang et al. [29]: n=56. Overall overlap between K542N and
G608G expression signatures: 90 genes (13.7%; 90/657). Overlap between the
two G608G expression signatures: 20 genes.
doi:10.1371/journal.pone.0021433.t001
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specimens from a homozygous K542N patient showed diffuse
WNT5A expression in all four layers of the epidermis, in contrast
to control skin where it was restricted to keratinocytes of the basal
epidermal layer (Figure 2C).
Discussion
This study provides the first detailed molecular biological
analysis of lamin A and C-related, hereditary HGPS relating the
transcriptional signature to the respective biochemical and
phenotypic features and comparing it with lamin A-related,
sporadic progeria. By investigating a consanguineous family with 4
affected children carrying a homozygous LMNA mutation
(c.1626G.C; p.K542N) we previously provided evidence for an
autosomal recessive form of HGPS, thus challenging the prevailing
view that HGPS merely represents a sporadic autosomal
dominant, lamin A-related laminopathy. Here we confirm our
previous assumption [4], that K542N does neither affect LMNA
mRNA splicing nor lamin A processing. Meanwhile, similar
observations have been reported in a 2-year-old HGPS patient
with age-pronounced acro-osteolysis who carried compound
heterozygous mutations, p.T528M and p.M540T, localized in
the C-terminal globular domain shared by both A-type lamins,
with no apparent effect on prelamin A processing [23]. The fact
that not only pre-lamin A accumulation but also mutations
affecting both A-type lamins can result in progeroid disease points
to common molecular mechanisms underlying both, lamin A-
(sporadic) and lamin A and C-related (hereditary) HGPS.
Distinct morphological abnormalities in LMNA
K542/K542N
fibroblast nuclei
Comparison of the nuclear morphology revealed that the
structural abnormalities of the nuclear lamina in LMNA
K542/K542N
fibroblasts substantially differs from those reported for sporadic
HGPS [16,17,20]. In particular, similar to nuclei from the
LMNA
T528M/M540T patient [23], nuclei of our patients did not
demonstrate multilobulation, but showed extensive protrusions
frequently present at opposite poles, accompanied with honey-
comb structures (Figure 1). Interestingly, similar to observations in
the parents of the LMNA
T528M/M540T patient [23], fibroblasts from
the three healthy heterozygous K542N carriers showed similar
nuclear protrusions, however, at a considerably lower frequency
compared to the homozygous patients (5% vs. 28%). LMNA
K542/
K542N nuclei displayed partial mislocalization of emerin in most of
the protrusions with a honeycomb pattern which hasn’t been
observed in LMNA
G608G/+ fibroblasts [18,46]. Likewise, loss of
lamin B1 within nuclear blebs, observed in our patients and the
T528M/M540T patient, does not represent a typical nuclear
abnormality in sporadic HGPS [20]. A reduction of the cellular
amount of lamin B proteins, described in LMNA
G608G/+ cells, could
not be confirmed by Western blotting in LMNA
K542/K542N
fibroblasts due to due to shortage of biological material.
Microarray analysis, however, showed no transcriptional changes
of LMNB1 and LMNB2, encoding lamin B1 and B2. In contrast
to sporadic HGPS, K542N does not lead to LAP2 loss, but to its
striking accumulation at the frontal edges of the nuclear
protrusions, even though lamin A is frequently lost in these
regions. This supports our previous assumption that K542N
mutation impairs the association of the LAP2-lamin A complexes
[4,25,47].
Our analysis of lamin A in skin and liver tissue provides direct
evidence that the K542N mutation results in aberrant nuclear
morphology in vivo. Thus far, in vivo effects of the G608G LMNA
mutation were only indirectly assessed in a mouse line expressing
human progerin in the epidermis [48]. In these mice keratinocyte
nuclei had severe defects, including envelope lobulation and
decreased nuclear circularity. Despite these defects, however,
transgenic mice did not develop any of the skin abnormalities
typical for HGPS. In contrast to the histopathological skin
alterations in our patient, the hepatic nuclear abnormalities were
not associated with any overt liver disease phenotype.
Transcriptional signatures in LMNA
K542/K542N fibroblasts
Comparison of the global gene expression profile in primary
cultured skin fibroblasts from affected LMNA
K542/K542N, healthy
LMNA
K542/+ carriers and controls revealed the deregulation of 657
genes involved in developmental and cell differentiation pathways.
LMNA
K542/K542N and LMNA
G608G/+ fibroblasts showed substantial
overlap in transcriptional signatures (13.7%; 90/657) [28,29].
Among these were several genes, whose mutations caused human
and/or mouse disorders that are either part of the HGPS
phenotypic spectrum or affect tissues and/or organs which are
also affected in HGPS. Seventy-five genes with a common
transcriptional signature (83.3%) displayed concordant (matching)
and 15 (16.7%) discordant (opposite) transcription patterns.
Among the differentially expressed genes specifically up-
regulated in hereditary HGPS was the Wnt5a ligand, a member
of the non-canonical Wnt signaling pathway, whose pathogenic
role in vivo could be evidenced by increased expression in skin from
an affected LMNA
K542/K542N carrier. Wnt5a signaling is essential
for normal developmental morphogenesis resulting in abnormal
craniofacial and skeletal development in Wnt5a null mice [49,50],
and Robinow Syndrome in humans [51]. Moreover, Wnt5a was
shown to be an important player in the decision-making process
whether bone marrow mesenchymal cells differentiate into
adipocytes or osteoblasts [45]. Since altered bone and fat
metabolism belong to the major features of HGPS and other
LMNA-associated progeroid disorders, the role of WNT5A in
disease pathophysiology clearly warrants further investigations
with the prospect to identify novel therapeutic avenues.
Concordant transcriptional alterations in lamin A- and
lamin A/C-related HGPS
Among the genes down-regulated in both HGPS types was
TWIST2, a known transcription factor important for osteoblast
differentiation and member of the NF-kB signalling pathway,
whose knock-out (Twist2
2/2) mouse model on a 129 genetic
background displays a cachectic phenotype similar to HGPS
[31,32]. These mice are normal at birth, but thereafter develop
severe wasting accompanied by adipose deficiency, skin atrophy
with hyperkeratosis, absence/reduction of hair follicles and
resulting in perinatal death from cachexia. On a 129/C57 mixed
background, Twist2
2/2 mice develop a milder phenotype, similar
to that of Setleis syndrome patients [32,52], who develop focal
facial dermal dysplasia, characterized by focal loss of subcutaneous
fat and dermal appendages. Recently, homozygous nonsense
mutations in TWIST2 were described in patients with Setleis
syndrome confirming that inactivation of TWIST2 leads to a
similar phenotype in humans [52]. Gene expression studies in
sporadic and hereditary HGPS revealed a 3-fold down-regulation
of TWIST2 in cultured fibroblasts [28]. Immunohistochemical
assessment of TWIST2 expression in skin from a homozygous
K542N carrier provided in vivo evidence for its role in the
pathogenesis of HGPS, with TWIST2 expression being lost in
fibroblasts and periadenexial cells of the dermis. In mice, Twist2 is
expressed in the dermis as well as in the dermal sheath of mature
hair follicles. The extensive phenotypic overlap between HGPS
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2/2 mice, provides
further evidence for a pivotal role of TWIST2 in HGPS skin
disease (Table 2).
Discordant transcriptional alterations in lamin A- and
lamin A/C-related HGPS
Comparison of the transcriptional signatures between
LMNA
K542/K542N and LMNA
G608G/+ fibroblasts revealed 15
(16.7%) genes with opposite changes in gene expression, among
two known regulators of vascular calcification and bone
metabolism, ENPP1 and OPG (TNFRSF11B) [28]. Intriguingly,
cardiovascular as well as bone disease represent major discordant
phenotypic features in sporadic and hereditary HGPS. Whereas
the latter is not associated with cardiovascular disease but exhibits
severe focal osteolysis, sporadic HGPS is characterized by
progressive cardiovascular disease with profound systemic adven-
titial fibrosis, frequent stenosis and calcification, as well as
generalized features of atherosclerosis [38,53,54]. Unlike patients
homozygous for K542N who die of respiratory failure due to
severe pneumonia, the major cause of death in sporadic HGPS is
myocardial infarction and stroke.
ENPP1 is a cell surface enzyme generating inorganic pyrophos-
phate (PPi), an essential physiologic inhibitor of calcification.
Mutations decreasing ENPP1 activity are associated with idio-
pathic infantile arterial calcification (GACI) as well as autosomal-
recessive hypophosphatemic rickets [35,55,56]. Considering that a
30% decrease in ENPP1 activity was already reported to cause
GACI, the observed 6.8-fold decrease in ENPP1 expression in
LMNA
G608G/+ is expected to substantially contribute to vascular
calcification whereas the 2.4-fold increase in LMNA
K542/K542N
fibroblasts may actually be protective with regard to vascular
disease [28].
OPG is a member of the OPG/RANK/RANKL cytokine triad and
a major secreted inhibitor of osteoclast maturation and activity
[57,58]. Increased OPG levels have been associated with the
incidence and prevalence of vascular calcification and hence
cardiovascular disease [33,34], as well as with inactivating
mutations in a hereditary bone disorder, autosomal recessive
Juvenile Paget disease [59,60,61]. Accordingly, increased expres-
sion of OPG in sporadic HGPS is expected to have an impact on
vascular calcification and disease, and, conversely, decreased
expression in hereditary HGPS on bone disease. Thus the opposite
expression patterns in ENPP1 and OPG provide plausible
molecular explanations for major phenotypic differences in
sporadic and hereditary HGPS and point to common, but
divergent underlying pathophysiological processes [4,62]. Clearly,
the extent of the contribution of ENPP1 and OPG to the
development of cardiovascular and bone disease needs to be
further assessed. If confirmed, HGPS patients with decreased
levels of OPG may actually profit from the treatment with
recombinant osteoprotegerin which was shown to decrease bone
resorption in patients with Juvenile Paget disease [63].
The different expression profiles regarding bone metabolism in
sporadic and hereditary HGPS are likely to reflect differences in
glucose metabolism. In contrast to patients with sporadic disease,
who were shown in some cases to manifest insulin resistance or
diabetes [5,64], our patients displayed increased insulin sensitivity
accompanied with elevated serum osteocalcin levels. C-peptide
measurements in the elder affected sibs were repeatedly found to
be very low, accompanied with decreased fasting and postprandial
insulin levels during oGTT. Intriguingly, our findings point to a
possible heterozygote effect since all LMNA K542N heterozygous
family members, including the 16 year old heterozygous sister of
the patients, showed moderately increased insulin sensitivity and
reduced insulin response of the b–cell to glucose uptake, which led
to impaired glucose tolerance/diabetes in the parents. Therefore,
increased insulin sensitivity in the homozygous patients may
actually be protective with regard to the consequences (diabetes) of
reduced b–cell function. Furthermore, the fact that LMNA
mutations can cause both, severe insulin resistance [65,66,67]
and increased insulin sensitivity in target tissues, convincingly
illustrates the pivotal role of A-type lamins in the regulation of
glucose metabolism. Clearly, the possibly age related reduction of
c-peptide levels observed in LMNA K542N homozygotes needs to
be confirmed in larger studies.
Previous discoveries in mice and human showed that osteocal-
cin, an osteoblast specific protein, acts as a hormone that increases
insulin production, insulin sensitivity, and regulates fat deposition
[44,68,69,70,71]. Intriguingly, very recent findings of two
independent laboratories provide support that the complete bone
remodeling process is involved in regulating energy metabolism,
thus linking skeletal homeostasis to energy regulation [72,73].
According to these findings, insulin signaling in osteoblasts
mediates glucose homeostasis by stimulating the production of
an inactive carboxylated form of osteocalcin and through down-
regulation of OPG promotes osteoclast mediated bone resorption,
which then releases the active undercarboxylated form of
osteocalcin (Figure 3A; [74]). Interestingly, Fulzele et al. provided
in vivo evidence that insulin signaling promotes bone formation by
suppressing an inhibitor of osteoblast development, Twist2, and
enhances expression of osteocalcin [72]. In line with this, the
increased levels of osteocalcin detected in our patients could be
due to down-regulation of TWIST2, with increased insulin
sensitivity caused by increased bone resorption promoted by
down-regulation of OPG (Figure 3B; [73]). Unfortunately, due to
Table 2. Phenotypic overlap between HGPS, Setleis syndrome patients, and Twist2
2/2 mice.
HGPS patients Setleis syndrome patients [52] Twist2
2/2 129/C57 mice [52] Twist2
2/2 129 mice [32]
Skin changes generalized focal focal generalized
Subcutaneous fat reduced near absence absent prominently reduced
Hair alopecia sparse hair alopecia sparse hair
Hair follicles absent n.m. absent reduced
Sebaceous glands absent n.m absent n.m.
Sweat glands present n.m. absent n.m.
Eyelashes absent absent lower eyelashes absent lower eyelashes n.m.
Note: n.m. denotes ‘‘not mentioned’’.
doi:10.1371/journal.pone.0021433.t002
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serum OPG, undercarboxylated osteocalcin, as well as adiponec-
tin, a known adipocyte specific cytokine regulated by osteocalcin
and influencing insulin sensitivity [75].
Our findings raise many questions regarding energy metabolism
not only in HGPS but, in view of recent discoveries in the field,
also in humans in general. With the active form of osteocalcin
being known as a potent stimulator of insulin secretion, the
seemingly contradictory observations of increased osteocalcin
levels and low levels of C-peptide and insulin observed in LMNA
K542N homozygotes suggest the presence of other factors
regulating insulin synthesis. Since insulin also has an impact on
bone metabolism (Figure 3B, [44,72,73,76,77,78]), it remains to be
assessed whether decreased insulin production in K542N homo-
zygotes directly contributes to bone disease. Because the liver is an
important organ for energy balance and glucose metabolism [79],
it remains to be seen if in vivo loss of TWIST2, observed in
hepatocyte nuclei, affects insulin sensitivity/resistance and energy
balance in hereditary HGPS. Do increased osteocalcin levels
contribute to lipodystrophy given that its active (uncarboxylated)
form is inversely correlated with fat deposition in mice and
humans [71,73,80]? Since TWIST2 down-regulation has been
observed in both HGPS types, inactive (carboxylated) osteocalcin
levels are likely to be elevated in sporadic HGPS, too. Given the
importance of osteocalcin in bone mineralization [81], do different
ratios of active/inactive osteocalcin help to explain the differences
in bone disease observed in sporadic and hereditary HGPS?
Considering the reciprocal regulation of bone and energy
metabolism, in which adipose tissue also controls bone remodeling
[82], it remains to be answered which of the initial HGPS-related
disease manifestations (failure to thrive, lipodystrophy, and bone
disease [2,4,5,62]) represent primary and which merely secondary
consequences?
Altogether, our data indicate that the most typical symptoms of
HGPS, such as bone disease, lipodystrophy, altered glucose
metabolism, and cardiovascular disease are intimately linked and
may be a consequence of altered skeletal and energy homeostasis.
Clearly, our findings need to be confirmed in larger studies in
order to further confirm the link between altered bone remodeling
and energy homeostasis in hereditary HGPS. Our extensive
comparative gene expression study corroborated by related clinical
investigations has delineated several molecular processes altered in
both of lamin A- and lamin A/C-related HGPS. Among the genes
down-regulated in both types of HGPS is TWIST2, a known
inhibitor of osteoblast development and member of the NF-kB
signalling pathway, whose inactivation in mice and humans results
in loss of subcutaneous fat and dermal appendages. Therefore,
TWIST2 loss detected in fibroblasts and periadenexial cells of the
dermis from a homozygous LMNA K542N patient provides direct
in vivo evidence for its role in HGPS skin pathogenesis. Our
observations of opposite transcriptional profiles in two key
mediators of bone metabolism and vascular calcification, ENPP1
and OPG, provide an explanation for divergent disease expression
in sporadic and hereditary HGPS, i.e. the extent of vascular and
bone disease. Further, this study correlates reduced TWIST2 and
OPG expression with increased osteocalcin levels and, consequent-
ly, insulin sensitivity, thereby linking altered bone remodeling to
energy homeostasis in hereditary HGPS. Thus, this study
recapitulates several recent findings on mouse models for bone
remodeling and energy metabolism and exemplifies the value of
hereditary disorders in delineating the mechanisms regulating
energy homeostasis in humans.
Materials and Methods
Material
The clinical and LMNA mutation data on the autosomal
recessive HGPS family has been previously reported [4]. In this
study, we examined primary skin fibroblasts from affected
homozygous (n=3), healthy heterozygote carriers (n=3), and
healthy controls (n=3), as well as autoptic skin and liver biopsies
from a deceased family member. In addition, detailed clinical and
laboratory follow-up of the family was undertaken.
Ethics Statement
This study was approved by the ethics board of S.B. Devi
Charity Home, Kolkata, India, and written informed consent was
obtained from all family members.
mRNA analysis
Total RNA was isolated from the primary skin fibroblasts
(passage 2; 60-70% confluency) of affected homozygous K542N
carriers (n=3), healthy heterozygotes (n=3), and wild-type
controls (n=3) using RNeasy Mini Kit (QIAGEN, Switzerland).
Cells were lysed directly on the 100 mm culture plates using Buffer
RLT and subsequently homogenized using QIAshredder spin
columns (QIAGEN, Switzerland). RNA was extracted according
to the manufacturer’s protocol, quantified on NanoDrop 3300
(Thermo Scientific, Switzerland), and quality assessed on RNA
Nano 6000 Chips (2100 Bioanalyzer, Agilent).
The K542N mRNA splicing was analyzed by reverse
transcriptase (RT)-PCR using following primers: forward primer
LMNA-ex8-12-F was located in exon 8 (59-ACTGGAGTC-
CACTGAGAGCC-39) and reverse primer LMNA-ex8-12-R in
exon 12 (59-GGCATGAGGTGAGGAGGAC-39). RT-PCR and
PCR were performed by means of QIAGEN OneStep RT-PCR
Kit (QIAGEN, Switzerland) according to the manufacturer’s
protocol.
Western analysis
Whole cells (2610
6) were collected, washed in PBS, and the
pellets were resuspended in RIPA buffer containing a Halt
Protease Inhibitor Cocktails (Thermo Scientific, Switzerland).
Protein content was measured using BCA (bicinchoninic acid)
protein assay (Thermo Scientific, Switzerland). Twenty micro-
grams of protein were loaded and electrophoresed on an 8%
Figure 3. Effects of the LMNA K542N mutation on bone remodeling and energy metabolism through the insulin/osteocalcin axis. (A)
Energy regulation and bone turnover by insulin signaling, adapted from Rosen and Motyl [74]. Insulin binds to the insulin receptor (IR) and activates
bone remodeling by increasing bone formation by osteoblasts (through down-regulation of Twist2) and resorption by osteoclasts (though down-
regulatin of OPG). Bone formation is coupled with the production of inactive (carboxylated) osteocalcin which is then released in an active form
(undercarboxylated) during bone resorption and enters into the circulation. The active, hormonal form of osteocalcin enhances insulin secretion and
increases the insulin sensitivity of adipocytes. (B) Altered regulation of energy metabolism and bone turnover in hereditary HGPS. In a homozygous
state, the LMNA K542N mutation leads to the down-regulation of TWIST2 and subsequent increased production of inactive osteocalcin. Decreased
expression of OPG in LMNA K542N homozygotes enhances bone resorption, which then increases the release of the active, hormonal form of
osteocalcin, and consequently results in increased insulin sensitivity. In a heterozygous state, the LMNA K542N mutation might overrule increased
insulin sensitivity.
doi:10.1371/journal.pone.0021433.g003
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transferred onto a nitrocellulose membrane (Amersham Biosci-
ences, Switzerlend), blocked with bovine serum albumin (3%), and
incubated with anti-lamin A (133A2; ab8980, Abcam), anti-lamin
A/C (JOL5, Acris Antibodies), and anti-actin (ab3280; Abcam)
antibody as a loading control. After several washings, membranes
were incubated with peroxidase-conjugated antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA), and immuno-
blots visualized by SuperSignal (Thermo Scientific, Switzerland).
Immunofluorescence and nuclear morphometric analysis
To determine whether the K542N mutation leads to defects in
nuclear architecture, immunofluorescence analysis of primary
cultured skin fibroblasts (passages 2–5) was performed, using the
following antibodies: anti-lamin A (133A2; ab8980, Abcam, and
ab26300, Abcam), anti-lamin A/C (JOL5, Acris Antibodies), anti-
LAP2 (27/LAP2, 611000, BD Biosciences, Milian, Switzerland),
and anti-emerin (ab14208, Abcam). Shortly, cells were fixed 20
minutes in 2% PFA, permealized with 0.05% Triton X-100 for 5
minutes, and stained 1 hour with primary antibodies, followed by
Alexa fluor 488 and 594 (Invitrogen), and mounted in ProLong
Gold anti-fade reagent with DAPI (Invitrogen, Switzerland). Cells
were observed on a Zeiss Axioskop optical microscope and Zeiss
LSM 510 Meta confocal microscope (Zeiss, Germany). The overall
percentage of malformed nuclei was scored in 200 nuclei, in a
double-blind count. Because nuclei of K542N carriers manifested
mostly single extensive lobe with typical ragged shape, the nuclei
were scored as lobulated if they contained at least one such lobe.
Statistical analyses were performed using unpaired, two-tailed
Student’s t test.
Gene Expression profiling
Total RNA isolated from the primary skin fibroblasts (see above)
was subjected to synthesis of double-stranded cDNA and biotin-
labelled cRNA using GeneChip Expression 39 Amplification One-
Cycle Target labeling and Control reagents according to the
manufacturer’s protocol (Affymetrix). Fragmented cRNA prepa-
rations were hybridized to GeneChipH Human Genome U133
Plus 2.0 arrays (Affymetrix UK Ltd.) and scanned on a GeneChip
Scanner 3000 7G (Affymetrix). All experiments were performed at
the core facility, Life Sciences Training Facility, Division of
Molecular Psychology, Biozentrum, and Department of Biomed-
icine, University of Basel. Microarray data is compliant to the
minimum information about a microarray experiment (MIAME)
criteria and is deposited at the European Bioinformatics Institute’s
ArrayExpress (www.ebi.ac.uk/arrayexpress; accession number E-
MEXP-3097).
Affymetrix GeneChip CEL data files were processed and
normalized using Robust Multi-Array (RMA) analysis and
differential expression assessed by empirical Bayesian approach,
as previously described [83]. P-value of ,0.05 and fold change of
1.5 were used as a criteria to select the statistically significant
differentially expressed genes. In addition, Ingenuity Pathways
Analysis (Ingenuity Systems, www.ingenuity.com) software was
used for interpretation of the results.
Real-time quantitative PCR
Validation of the selected differentially expressed genes was
performed using TaqMan Gene Expression Assays (Table S2;
Applied Biosystems, Switzerland), according to the manufacturer’s
protocol. Actin, beta (ACTB) was used as an endogenous control
and all reactions performed in triplicates. Relative gene expression
changes were calculated using using the 2
2DDCT method [84].
Pathological examinations
Immunohistochemical evaluation of LMNA, TWIST2, and
WNT5A was performed in skin and/or liver autoptic specimens
from a deceased K542N homozygous patient according to the
protocol previously described [85], using following antibodies:
anti-lamin A (ab26300, Abcam), anti-Twist2 (3C8, M01, Abnova
Corporation), and anti-Wnt5a (AF645, R&D Systems). Periodic
acid-Schiff (PAS) staining for glycogen was performed using the
standard procedures [86].
Laboratory tests
The follow-up examination of insulin, C-peptide, glucose and
lipids was performed in three patients, and healthy parents and
sister and analyzed in the medical diagnostic laboratory Viollier
AG (Switzerland). In a second, independent investigation, oral
glucose tolerance testing was performed in two patients (A: male,
age of 10, body weight (BW) 12 kg; E: male, age of 20, BW 13 kg)
as well as the healthy parents (mother: age of 42, BW 60 kg;
father: age of 47, BW 55 kg). After 12 hours of fasting the
patients and their parents receiving 1.75 g of glucose per
kilogram of body weight (maximum 75 g). Serum glucose and
insulin were measured in Drs. Tribedi & Roy Diagnostic
Laboratory (Kolkata, India) at 0 and 2 hours. Assessment of C-
peptide and osteocalcin was performed at the medical diagnostic
laboratory Viollier AG, Switzerland, and of TNF-alpha at the
University Hospital, Zuerich. To assess insulin resistance, b-cell
function and insulin sensitivity a nonlinear homeostatic model
assessment (HOMA2) was undertaken [40]. In addition, indices
derived from the oGTT were used to evaluate insulin sensitivity
[42,43]. Electrocardiogram and echocardiographic investigations
were performed at the Institute of Child Health, Kolkata, and
computed tomography (CT) imaging of the heart and the large
vessels was performed at EKO X-Ray and Imaging Institute,
Kolkata, India.
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